Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo New Products Include Branded Weight-Loss Supplement, Kid’s Multi

This article was originally published in The Tan Sheet

Executive Summary

Perrigo introduced two branded products developed in-house at the National Association of Chain Drug Stores Marketplace June 8-10: Dr. Steven Rosenblatt's Ephedra Free Starch Blocker with Phase 2 Starch Neutralizer and Sesame Street Complete Children's Multivitamin Multimineral Supplement
Advertisement

Related Content

NACDS In Brief
Perrigo Sees Long-Term Growth In Vitamins; Cough/Cold Sales Down
Bear Stearns Healthcare Conference In Brief
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo To Enter Generic Rx Drug Market With OTC Experience In Mind
Robitussin CoughGels Dedicated Ads Planned During Cough/Cold Season
Perrigo’s Loratadine 505(b)(2) NDA Was Properly Submitted, Firm Maintains
Perrigo Loses Acetaminophen Supplier, Gains Loratadine Deal
Natrol Alternative Kava Supplement, New Labeling Debuts At Expo West
Natrol Alternative Kava Supplement, New Labeling Debuts At Expo West

Topics

Advertisement
UsernamePublicRestriction

Register

PS095612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel